Search

Your search keyword '"Herishanu, Yair"' showing total 676 results
Start Over Author "Herishanu, Yair"
676 results on '"Herishanu, Yair"'

52. Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.

Author

Johnson, Nathalie A., primary, Lavie, David, additional, Borchmann, Peter, additional, Gregory, Gareth, additional, Herrera, Alex Francisco, additional, Minuk, Leonard, additional, Vucinic, Vladan, additional, Armand, Philippe, additional, Avigdor, Abraham, additional, Gasiorowski, Robin, additional, Herishanu, Yair, additional, Keane, Colm, additional, Kuruvilla, John, additional, Palcza, John, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Timmerman, John, additional

Published
2022
Full Text
View/download PDF

53. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.

Author

Sharman, Jeff Porter, primary, Egyed, Miklos, additional, Jurczak, Wojciech, additional, Skarbnik, Alan P., additional, Kamdar, Manali K., additional, Munir, Talha, additional, Fogliatto, Laura, additional, Herishanu, Yair, additional, Banerji, Versha, additional, Follows, George, additional, Walker, Patricia, additional, Karlsson, Karin, additional, Ghia, Paolo, additional, Janssens, Ann, additional, Ferrant, Emmanuelle, additional, Munugalavadla, Veerendra, additional, Yu, Ting, additional, Wang, Min Hui, additional, and Woyach, Jennifer Ann, additional

Published
2022
Full Text
View/download PDF

54. COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Author

Bronstein, Yotam, primary, Gat, Roi, additional, Levi, Shai, additional, Cohen, Yael C., additional, Luttwak, Efrat, additional, Benyamini, Noam, additional, Shragai, Tamir, additional, Vitkon, Roy, additional, Neaman, Miriam, additional, Eilaty, Nili, additional, Levi, Mor, additional, Trestman, Svetlana, additional, Perry, Chava, additional, Herishanu, Yair, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

56. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, Ghia, Paolo, Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2022

58. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients

Author

Saiag, Esther, primary, Grupper, Ayelet, additional, Avivi, Irit, additional, Elkayam, Ori, additional, Ram, Ron, additional, Herishanu, Yair, additional, Cohen, Yael, additional, Perry, Chava, additional, Furer, Victoria, additional, Katchman, Helena, additional, Rabinowich, Liane, additional, Ben-Yehoyada, Merav, additional, Halperin, Tami, additional, Baruch, Roni, additional, Goldshmidt, Hanoch, additional, Hagin, David, additional, Ben-Ami, Ronen, additional, Sprecher, Eli, additional, and Bomze, David, additional

Published
2022
Full Text
View/download PDF

59. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Gonzales, Monica Baile, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Poeta, Giovanni Del, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, García-Marco, José A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Silva, Maria Gomes, additional, Gutwein, Odit, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Bastida, Carlota Mayor, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Raa, Doreen Te, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Spek, Ellen Der, additional, Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

61. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

Author

Herishanu, Yair, Pérez-Galán, Patricia, Liu, Delong, Biancotto, Angélique, Pittaluga, Stefania, Vire, Berengere, Gibellini, Federica, Njuguna, Ndegwa, Lee, Elinor, Stennett, Lawrence, Raghavachari, Nalini, Liu, Poching, McCoy, J. Philip, Raffeld, Mark, Stetler-Stevenson, Maryalice, Yuan, Constance, Sherry, Richard, Arthur, Diane C., Maric, Irina, White, Therese, Marti, Gerald E., Munson, Peter, Wilson, Wyndham H., and Wiestner, Adrian

Published
2011
Full Text
View/download PDF

66. Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study

Author

Herishanu, Yair, primary, Goldschmidt, Neta, additional, Itchaki, Gilad, additional, Levi, Itai, additional, Aviv, Ariel, additional, Fineman, Riva, additional, Dally, Najib, additional, Tadmor, Tamar, additional, Ruchlemer, Rosa, additional, Abadi, Uri, additional, Shvidel, Lev, additional, Braester, Andrei, additional, Cohen, Raanan, additional, Frankel, Neta, additional, Ofek, Keren, additional, Berelovich, Jenia, additional, Grunspan, Moshe, additional, and Benjamini, Ohad, additional

Published
2021
Full Text
View/download PDF

67. Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Author

Herishanu, Yair, primary, Levi, Shai, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Bairey, Osnat, additional, Del Poeta, Giovanni, additional, Ziv Baran, Tomer, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Breaster, Andrei, additional, Bronstein, Yotam, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonino, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foa, Robin, additional, Cuneo, Antonio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

69. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Author

Chatzikonstantinou, Thomas, primary, Scarfo, Lydia, additional, Demosthenous, Christos, additional, Kotaskova, Jana, additional, Iacoboni, Gloria, additional, Minga, Evangelia, additional, Chammou, Dimitra, additional, Karakatsoulis, Georgios, additional, Albi, Elisa, additional, Alcoceba, Miguel, additional, El-Ashwah, Shaimaa, additional, Bacchiarri, Francesca, additional, Khan, Mehreen Ali, additional, Aurran, Thérèse, additional, Calleja, Anne, additional, Cassin, Ramona, additional, Chatzileontiadou, Sofia, additional, Christian, Amy, additional, Claus, Rainer, additional, Collado, Rosa, additional, De Deus Santos, Marcos Daniel, additional, Davis, Zadie, additional, Dimou, Maria, additional, Donaldson, David, additional, Dos Santos, Gimena, additional, Dreta, Barbara, additional, Efstathopoulou, Maria, additional, Enrico, Alicia, additional, Fresa, Alberto, additional, Galimberti, Sara, additional, García-Serra, Rocío, additional, González-Gascón Y Marín, Isabel, additional, Gozzetti, Alessandro, additional, Guarente, Valerio, additional, Harrop, Sean, additional, Hatzimichael, Eleftheria, additional, Herishanu, Yair, additional, Inchiappa, Luca, additional, Iskas, Michalis, additional, Jaksic, Ozren, additional, Janssen, Susanne R., additional, Kalicinska, Elzbieta, additional, Karakus, Volkan, additional, Kater, Arnon P., additional, Kho, Bonnie, additional, Konstantinou, Iliana, additional, Longval, Thomas, additional, Koren-Michowitz, Maya, additional, Kotsianidis, Ioannis, additional, Kreitman, Robert J., additional, Nath, Uttam Kumar, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laribi, Kamel, additional, Levy, Ilana, additional, Lopez-Garcia, Alberto, additional, Marquet Palomanes, Juan, additional, Maslejova, Stanislava, additional, Mayor-Bastida, Carlota, additional, Merabet, Fatiha, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Miras, Fatima, additional, Moia, Riccardo, additional, Morawska, Marta, additional, Navarro-Bailón, Almudena, additional, Oscier, David, additional, Olivieri, Jacopo, additional, Papajík, Tomáš, additional, Papaioannou, Maria, additional, Pierie, Cheyenne, additional, Puiggros, Anna, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Schiattone, Luana, additional, Sevindik, Omur Gokmen, additional, Shen, Yandong, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Soliman, Dina Sameh, additional, Špaček, Martin, additional, Schiwitza, Annett, additional, Tadmor, Tamar, additional, Tourjeman, Liat, additional, Tse, Eric, additional, Visentin, Andrea, additional, Tomic, Kristina, additional, Van Gelder, Michel, additional, Vassilakopoulos, Theodoros P., additional, Vitale, Candida, additional, Vrachiolias, George, additional, Vukovic, Vojin, additional, Xu, Zhenshu, additional, Yáñez, Lucrecia, additional, Yagci, Munci, additional, Yassin, Mohamed A, additional, Zuchnicka, Jana, additional, Angelopoulou, Maria K., additional, Antic, Darko, additional, Biderman, Bella V., additional, Catherwood, Mark, additional, Coscia, Marta, additional, Cuneo, Antonio, additional, Demirkan, Fatih, additional, Espinet, Blanca, additional, Gaidano, Gianluca, additional, Guièze, Romain, additional, Kalashnikova, Olga, additional, Laurenti, Luca, additional, Mulligan, Stephen, additional, Murru, Roberta, additional, Nikitin, Eugene A., additional, Panayiotidis, Panayiotis, additional, Pangalis, Gerasimos, additional, Panovska, Irina, additional, Popov, Viola Maria, additional, Pospíšilová, Šárka, additional, Smolej, Lukas, additional, Sportoletti, Paolo, additional, Stavroyianni, Niki, additional, Tam, Constantine S., additional, Trentin, Livio, additional, Trněný, Marek, additional, Bosch Albareda, Francesc, additional, Doubek, Michael, additional, Chatzidimitriou, Anastasia, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2021
Full Text
View/download PDF

71. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells

Author

Beyar‐Katz, Ofrat, primary, Kikozashvili, Nino, additional, Bar On, Yael, additional, Amit, Odelia, additional, Perry, Chava, additional, Avivi, Irit, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Duek, Adrian, additional, Ben‐Ami, Ronen, additional, Shasha, David, additional, and Ram, Ron, additional

Published
2021
Full Text
View/download PDF

72. Poster: CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up

Author

Sharman, Jeff P., primary, Egyed, Miklos, additional, Jurczak, Wojciech, additional, Skarbnik, Alan, additional, Pagel, John M., additional, Flinn, Ian W., additional, Kamdar, Manali, additional, Munir, Talha, additional, Walewska, Renata, additional, Corbett, Gillian, additional, Fogliatto, Laura Maria, additional, Herishanu, Yair, additional, Banerji, Versha, additional, Coutre, Steven, additional, Follows, George, additional, Walker, Patricia, additional, Karlsson, Karin, additional, Ghia, Paolo, additional, Janssens, Ann, additional, Cymbalista, Florence, additional, Woyach, Jennifer A., additional, Ferrant, Emmanuelle, additional, Wierda, William G., additional, Munugalavadla, Veerendra, additional, Patel, Priti, additional, Wang, Min Hui, additional, and Byrd, John C., additional

Published
2021
Full Text
View/download PDF

73. CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up

Author

Sharman, Jeff P., primary, Egyed, Miklos, additional, Jurczak, Wojciech, additional, Skarbnik, Alan, additional, Pagel, John M., additional, Flinn, Ian W., additional, Kamdar, Manali, additional, Munir, Talha, additional, Walewska, Renata, additional, Corbett, Gillian, additional, Fogliatto, Laura Maria, additional, Herishanu, Yair, additional, Banerji, Versha, additional, Coutre, Steven, additional, Follows, George, additional, Walker, Patricia, additional, Karlsson, Karin, additional, Ghia, Paolo, additional, Janssens, Ann, additional, Cymbalista, Florence, additional, Woyach, Jennifer A., additional, Ferrant, Emmanuelle, additional, Wierda, William G., additional, Munugalavadla, Veerendra, additional, Patel, Priti, additional, Wang, Min Hui, additional, and Byrd, John C., additional

Published
2021
Full Text
View/download PDF

77. Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies

Author

Shapira, Shiran, primary, Kazanov, Dina, additional, Mdah, Fatin, additional, Yaakobi, Hadas, additional, Herishanu, Yair, additional, Perry, Chava, additional, Avivi, Irit, additional, Itchaki, Gilad, additional, Shacham-Abulafia, Adi, additional, Raanani, Pia, additional, Hay-Levy, Mori, additional, Aiger, Gal, additional, Mashiah, Jacob, additional, Lev-Ari, Shahar, additional, and Arber, Nadir, additional

Published
2021
Full Text
View/download PDF

78. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study

Author

Ram, Ron, primary, Grisariu, Sigal, additional, Shargian-Alon, Liat, additional, Amit, Odelia, additional, Bar-On, Yaeli, additional, Stepensky, Polina, additional, Yeshurun, Moshe, additional, Avni, Batia, additional, Hagin, David, additional, Perry, Chava, additional, Gurion, Ronit, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Gold, Ronit, additional, Glait-Santar, Chen, additional, Kay, Sigi, additional, and Avivi, Irit, additional

Published
2021
Full Text
View/download PDF

79. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma

Author

Avivi, Irit, primary, Balaban, Roi, additional, Shragai, Tamir, additional, Sheffer, Gabi, additional, Morales, Miguel, additional, Aharon, Anat, additional, Lowenton‐Spier, Noa, additional, Trestman, Svetlana, additional, Perry, Chava, additional, Benyamini, Noam, additional, Mittelman, Moshe, additional, Tabib, Yaara, additional, Bar Lev, Tali, additional, Zavaro, Mor, additional, Herishanu, Yair, additional, Luttwak, Efrat, additional, and Cohen, Yael C., additional

Published
2021
Full Text
View/download PDF

80. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia, Marta Rambaldi, Alessandro and Montserrat, Emili Foa, Robin Cuneo, Antonio Stamatopoulos, Kostas Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2021

81. Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19

Author

Sarid,Nadav, Mann,Shir, Herishanu,Yair, Perry,Chava, Cohen,Yael C, Passage,Inna, Neaman,Miriam, Benyamini,Noam, Jean,Maayan, Avivi,Irit, Sarid,Nadav, Mann,Shir, Herishanu,Yair, Perry,Chava, Cohen,Yael C, Passage,Inna, Neaman,Miriam, Benyamini,Noam, Jean,Maayan, and Avivi,Irit

Abstract

Nadav Sarid,1,2 Shir Mann,1 Yair Herishanu,1,2 Chava Perry,1,2 Yael C Cohen,1,2 Inna Passage,1 Miriam Neaman,1,2 Noam Benyamini,1,2 Maayan Jean,1 Irit Avivi1,2 1Departments of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence: Irit AviviDepartment of Hematology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv, 6423906, IsraelTel +972-3-6973576Fax +972-3-6974452Email iritavi@tlvmc.gov.ilObjective: Hemato-oncology patients are at high risk for morbidity and mortality from coronavirus disease (COVID-19). The resultant heightened anxiety among these patients may negatively affect adherence to therapy and treatment-related outcome. We aimed to assess whether the adoption of precautionary measures provided by the medical team led to a reduction in COVID-19-related anxiety and, consequently, to successful execution of treatment plans.Methods: All adult hemato-oncology patients actively treated or being followed-up at the outpatient service at Tel Aviv Sourasky Medical Center between March 25 and May 3, 2020, were invited to answer a questionnaire that focused on their anxiety and adherence to treatment following new measures to reduce risk of infection during the first COVID-19 outbreak.Results: One hundred and fifty patients (representing 24% of those being approached), average age 67 years, 52% male, and 57% undergoing antineoplastic therapy, responded to the survey. The introduction of precautionary measures resulted in a significant reduction in anxiety level in all patients, irrespective of age, sex, or treatment status. Attendance to scheduled visits in day care and outpatient clinics remained unchanged. Adherence to planned blood and imaging tests were 81% and 73%, respectively, and 93% of the patients were satisfied with their medical care. Thirty-two percent of patients used telemedicine. Satisfaction with telemedicine was highest among non-actively treate

Published
2021

82. Measurable residual disease in chronic lymphocytic leukemia:expert review and consensus recommendations

Author

Wierda, William G., Rawstron, Andrew, Cymbalista, Florence, Badoux, Xavier, Rossi, Davide, Brown, Jennifer R., Egle, Alexander, Abello, Virginia, Cervera Ceballos, Eduardo, Herishanu, Yair, Mulligan, Stephen P., Niemann, Carsten U., Diong, Colin P., Soysal, Teoman, Suzuki, Ritsuro, Tran, Hoa T.T., Wu, Shang Ju, Owen, Carolyn, Stilgenbauer, Stephan, Ghia, Paolo, Hillmen, Peter, Wierda, William G., Rawstron, Andrew, Cymbalista, Florence, Badoux, Xavier, Rossi, Davide, Brown, Jennifer R., Egle, Alexander, Abello, Virginia, Cervera Ceballos, Eduardo, Herishanu, Yair, Mulligan, Stephen P., Niemann, Carsten U., Diong, Colin P., Soysal, Teoman, Suzuki, Ritsuro, Tran, Hoa T.T., Wu, Shang Ju, Owen, Carolyn, Stilgenbauer, Stephan, Ghia, Paolo, and Hillmen, Peter

Abstract

Assessment of measurable residual disease (often referred to as “minimal residual disease”) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic lymphocytic leukemia. Undetectable-measurable residual disease status at the end of treatment demonstrated independent prognostic significance in chronic lymphocytic leukemia, correlating with favorable progression-free and overall survival with chemoimmunotherapy. Given its utility in evaluating depth of response, determining measurable residual disease status is now a focus of outcomes in chronic lymphocytic leukemia clinical trials. Increased adoption of measurable residual disease assessment calls for standards for nomenclature and outcomes data reporting. In addition, many basic questions have not been systematically addressed. Here, we present the work of an international, multidisciplinary, 174-member panel convened to identify critical questions on key issues pertaining to measurable residual disease in chronic lymphocytic leukemia, review evaluable data, develop unified answers in conjunction with local expert input, and provide recommendations for future studies. Recommendations are presented regarding methodology for measurable residual disease determination, assay requirements and in which tissue to assess measurable residual disease, timing and frequency of assessment, use of measurable residual disease in clinical practice versus clinical trials, and the future usefulness of measurable residual disease assessment. Nomenclature is also proposed. Adoption of these recommendations will work toward standardizing data acquisition and interpretation in future studies with new treatments with the ultimate objective of improving outcomes and curing chronic lymphocytic leukemia.

Published
2021

85. Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Author

Santoro, Armando, Johnson, Nathalie A., Savage, Kerry J., Avigdor, Abraham, Bazargan, Ali, Borchmann, Peter, Gasiorowski, Robin, Gregory, Gareth P., Herishanu, Yair, Madan, Sumit, Minuk, Leonard, Musuraca, Gerardo, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia, and Zinzani, Pier Luigi

Published
2023
Full Text
View/download PDF

86. Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Author

Sharman, Jeff P., Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Patel, Krish, Flinn, Ian W., Kamdar, Manali, Munir, Talha, Walewska, Renata, Hughes, Marie, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Follows, George, Walker, Patricia A., Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Byrd, John C., Ferrant, Emmanuelle, Ferrajoli, Alessandra, Wierda, William G., Munugalavadla, Veerendra, Wachira, Catherine Wangui, Wun, Chuan-Chuan, and Woyach, Jennifer A.

Published
2023
Full Text
View/download PDF

88. Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Author

Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia, and Timmerman, John

Published
2023
Full Text
View/download PDF

90. Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Author

Roeker, Lindsey E, Scarfo, Lydia, Chatzikonstantinou, Thomas, Abrisqueta, Pau, Eyre, Toby A., Cordoba, Raul, Muntañola Prat, Ana, Villacampa, Guillermo, Leslie, Lori A., Koropsak, Michael, Quaresmini, Giulia, Allan, John N., Furman, Richard R., Bhavsar, Erica B, Pagel, John M., Hernandez-Rivas, Jose Angel, Patel, Krish, Motta, Marina, Bailey, Neil, Miras, Fatima, Lamanna, Nicole, Alonso, Rosalia, Osorio-Prendes, Santiago, Vitale, Candida, Kamdar, Manali, Baltasar, Patricia, Österborg, Anders, Hanson, Lotta, Baile, Mónica, Rodríguez-Hernández, Ines, Valenciano, Susana, Popov, Viola Maria, Barez Garcia, Abelardo, Alfayate, Ana, Oliveira, Ana C, Eichhorst, Barbara, Quaglia, Francesca M., Reda, Gianluigi, Lopez Jimenez, Javier, Varettoni, Marzia, Marchetti, Monia, Romero, Pilar, Riaza Grau, Rosalía, Munir, Talha, Zabalza, Amaya, Janssens, Ann, Niemann, Carsten U, Perini, Guilherme Fleury, Delgado, Julio, Yanez San Segundo, Lucrecia, Gómez Roncero, Ma Isabel, Wilson, Matthew, Patten, Piers, Marasca, Roberto, Iyengar, Sunil, Seddon, Amanda, Torres, Ana, Ferrari, Angela, Cuéllar-García, Carolina, Wojenski, Daniel, El-Sharkawi, Dima, Itchaki, Gilad, Parry, Helen, Mateos-Mazón, Juan José, Martinez-Calle, Nicolas, Ma, Shuo, Naya, Daniel, Van Der Spek, Ellen, Seymour, Erlene K., Gimeno Vázquez, Eva, Rigolin, Gian Matteo, Mauro, Francesca Romana, Walter, Harriet S, Labrador, Jorge, De Paoli, Lorenzo, Laurenti, Luca, Ruiz, Elena, Levin, Mark-David, Šimkovič, Martin, Špaček, Martin, Andreu, Rafa, Walewska, Renata, Perez-Gonzalez, Sonia, Sundaram, Suchitra, Wiestner, Adrian, Cuesta, Amalia, Broom, Angus, Kater, Arnon P., Muiña, Begoña, Velasquez, César A, Ujjani, Chaitra S., Seri, Cristina, Antic, Darko, Bron, Dominique, Vandenberghe, Elisabeth, Chong, Elise A., Lista, Enrico, García, Fiz Campoy, Del Poeta, Giovanni, Ahn, Inhye, Pu, Jeffrey J., Brown, Jennifer R, Soler Campos, Juan Alfonso, Malerba, Lara, Trentin, Livio, Orsucci, Lorella, Farina, Lucia, Villalon, Lucia, Vidal, Maria Jesus, Sanchez, Maria Jose, Terol, Maria Jose, De Paolis, Maria Rosaria, Gentile, Massimo, Davids, Matthew S., Shadman, Mazyar, Yassin, Mohamed A, Foglietta, Myriam, Jaksic, Ozren, Sportoletti, Paolo, Barr, Paul M., Ramos, Rafael, Santiago, Raquel, Ruchlemer, Rosa, Kersting, Sabina, Huntington, Scott F., Herold, Tobias, Herishanu, Yair, Thompson, Meghan C., Lebowitz, Sonia, Ryan, Christine, Jacobs, Ryan W., Portell, Craig A., Isaac, Krista, Rambaldi, Alessandro, Nabhan, Chadi, Brander, Danielle M., Montserrat, Emili, Rossi, Giuseppe, Garcia-Marco, Jose A., Sr., Coscia, Marta, Malakhov, Nikita, Fernandez-Escalada, Noemi, Skånland, Sigrid Strand, Coombs, Callie C., Ghione, Paola, Schuster, Stephen J., Foà, Robin, Cuneo, Antonio, Bosch, Francesc, Stamatopoulos, Kostas, Ghia, Paolo, Mato, Anthony R., and Patel, Meera

Published
2020
Full Text
View/download PDF

93. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Author

Morabito, Fortunato, primary, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Recchia, Anna Grazia, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Martino, Enrica Antonia, additional, Vigna, Ernesto, additional, Tripepi, Giovanni, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Cutrona, Giovanna, additional, Jaksic, Ozren, additional, Olivieri, Jacopo, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

94. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.

Author

Sharman, Jeff Porter, primary, Egyed, Miklos, additional, Jurczak, Wojciech, additional, Skarbnik, Alan, additional, Pagel, John M., additional, Kamdar, Manali K., additional, Munir, Talha, additional, Corbett, Gillian, additional, Fogliatto, Laura Maria, additional, Herishanu, Yair, additional, Banerji, Versha, additional, Coutre, Steve E., additional, Walker, Patricia, additional, Karlsson, Karin, additional, Ghia, Paolo, additional, Janssens, Ann, additional, Wierda, William G., additional, Patel, Priti, additional, Wang, Min Hui, additional, and Byrd, John C., additional

Published
2021
Full Text
View/download PDF

95. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells

Author

Shorer Arbel, Yamit, primary, Katz, Ben-Zion, additional, Gabizon, Ronen, additional, Shraga, Amit, additional, Bronstein, Yotam, additional, Kamdjou, Talia, additional, Globerson Levin, Anat, additional, Perry, Chava, additional, Avivi, Irit, additional, London, Nir, additional, and Herishanu, Yair, additional

Published
2021
Full Text
View/download PDF

96. Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Cassin, Ramona, additional, D′Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Monti, Paola, additional, Menichini, Paola, additional, Olivieri, Jacopo, additional, Cutrona, Giovanna, additional, Rossi, Davide, additional, Cuneo, Antonio, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

98. Spatial organization and early signaling of the B-cell receptor in CLL.

Author

Arbel, Yamit Shorer, Bronstein, Yotam, Dadosh, Tali, Kamdjou, Talia, Tsuriel, Shlomo, Shapiro, Mika, Katz, Ben-Zion, and Herishanu, Yair

Subjects
CHRONIC lymphocytic leukemia, IMMUNOGLOBULIN G, B cells
Abstract

Most chronic lymphocytic leukemia (CLL) clones express B-cell receptors (BcR) of both IgM/IgD isotypes; however, 5%-10% of CLL cases express isotypeswitched immunoglobulin G (IgG). The early signaling and spatial patterning of the various BcRs at steady state and after activation are still fully unresolved. Herein, we show higher expression of the BcR signalosome elements and a more robust constitutive cell-intrinsic proximal BcR signaling in CLL with unmutated IGHV expressing IgM isotype (IgM U-CLL), compared with IGHVmutated CLL (M-CLL) expressing either IgM or IgG isotypes. IgM in U-CLL is frequently located in the membrane plane in polarized patches, occasionally in caps, and sometimes inside the cells. Among M-CLL, IgM is scattered laterally in the membrane plane in a similar pattern as seen in normal B cells, whereas IgG is dispersed around the cell membrane in smaller clusters than in IgM U-CLL. Upon BcR engagement, both IgG and IgM expressing M-CLL showed attenuated signaling and only slight spatial reorganization dynamics of BcR microclusters and internalization, compared with the extensive reorganization and internalization of the BcR in IgM expressing U-CLL. The global gene signature of IgG M-CLL was closely related to that of IgM M-CLL rather than IgM U-CLL. Overall, we report fundamental differences in the basal composition, biochemical status, and spatial organization of the BcR in the three examined immunogenetic CLL subtypes that correlate with their clinical behavior. On the basis of our findings, IgG class-switched M-CLL likely represents the same disease as IgM M-CLL rather than a different biological and/or clinical entity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results